CN1473156A - 嘧啶衍生物及其作为神经肽y受体配体的用途 - Google Patents

嘧啶衍生物及其作为神经肽y受体配体的用途 Download PDF

Info

Publication number
CN1473156A
CN1473156A CNA018186343A CN01818634A CN1473156A CN 1473156 A CN1473156 A CN 1473156A CN A018186343 A CNA018186343 A CN A018186343A CN 01818634 A CN01818634 A CN 01818634A CN 1473156 A CN1473156 A CN 1473156A
Authority
CN
China
Prior art keywords
methyl
vinyl
phenyl
pyrimidine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018186343A
Other languages
English (en)
Chinese (zh)
Inventor
�ֿˡ��������
沃克·布罗伊
富兰克·道岑贝格
��¡���̫
帕特里奇奥·马太
���ε¹���
维尔纳·奈德哈德
�����շ�������˹��
菲利普·普夫利格纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1473156A publication Critical patent/CN1473156A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA018186343A 2000-11-10 2001-11-06 嘧啶衍生物及其作为神经肽y受体配体的用途 Pending CN1473156A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00124610.7 2000-11-10
EP00124610 2000-11-10

Publications (1)

Publication Number Publication Date
CN1473156A true CN1473156A (zh) 2004-02-04

Family

ID=8170342

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018186343A Pending CN1473156A (zh) 2000-11-10 2001-11-06 嘧啶衍生物及其作为神经肽y受体配体的用途

Country Status (20)

Country Link
US (1) US6657060B2 (https=)
EP (1) EP1335906B1 (https=)
JP (1) JP2004524279A (https=)
KR (1) KR100611853B1 (https=)
CN (1) CN1473156A (https=)
AR (1) AR034700A1 (https=)
AT (1) ATE340784T1 (https=)
AU (2) AU2790502A (https=)
BR (1) BR0115045A (https=)
CA (1) CA2427350A1 (https=)
DE (1) DE60123458T2 (https=)
DK (1) DK1335906T3 (https=)
ES (1) ES2271100T3 (https=)
MX (1) MXPA03004136A (https=)
PA (1) PA8531701A1 (https=)
PE (1) PE20020603A1 (https=)
PT (1) PT1335906E (https=)
UY (1) UY27018A1 (https=)
WO (1) WO2002038551A1 (https=)
ZA (1) ZA200302970B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015039292A1 (zh) * 2013-09-18 2015-03-26 华安医学股份有限公司 一种活化ampk的化合物及其用途
CN112375042A (zh) * 2020-10-27 2021-02-19 安徽医科大学 三甲氧基苯乙烯基六元环类和吡唑并嘧啶类化合物、制剂及其制备与应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
AU2003214110A1 (en) * 2002-03-15 2003-09-29 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
US7768604B2 (en) * 2005-09-20 2010-08-03 Au Optronics Corporation Transflective liquid crystal display with partially shifted reflectivity curve
GB0616747D0 (en) * 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
JP2009523161A (ja) * 2006-01-11 2009-06-18 アストラゼネカ アクチボラグ モルホリノピリミジン誘導体と療法におけるその使用
JP2010501537A (ja) * 2006-08-24 2010-01-21 アストラゼネカ アクチボラグ 増殖性障害の治療に有用なモルホリノピリミジン誘導体
MX2009002046A (es) * 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
WO2009007751A2 (en) * 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
EP2178866A2 (en) * 2007-07-09 2010-04-28 AstraZeneca AB Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
CA2692945A1 (en) * 2007-07-09 2009-01-15 Astrazeneca Ab Compounds - 945
CN101809002B (zh) 2007-07-09 2013-03-27 阿斯利康(瑞典)有限公司 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
EP2342191B1 (en) * 2008-09-10 2013-03-20 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogen-containing 6-membered ring compounds and their use
US20110053923A1 (en) * 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
JP2011201873A (ja) * 2010-03-03 2011-10-13 Mitsubishi Tanabe Pharma Corp 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用
WO2011112428A2 (en) * 2010-03-11 2011-09-15 Targacept, Inc. Arylvinylazacycloalkane compounds for constipation
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720467B2 (ja) * 1988-06-15 1995-03-08 松下電器産業株式会社 超音波診断装置
JPH024345A (ja) * 1988-06-15 1990-01-09 Matsushita Electric Ind Co Ltd 超音波変換装置
US5728704A (en) * 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
AU2042897A (en) 1996-03-21 1997-10-10 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives
WO1998040356A1 (en) * 1997-03-12 1998-09-17 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015039292A1 (zh) * 2013-09-18 2015-03-26 华安医学股份有限公司 一种活化ampk的化合物及其用途
CN112375042A (zh) * 2020-10-27 2021-02-19 安徽医科大学 三甲氧基苯乙烯基六元环类和吡唑并嘧啶类化合物、制剂及其制备与应用

Also Published As

Publication number Publication date
BR0115045A (pt) 2004-02-03
AU2002227905B2 (en) 2006-10-05
US6657060B2 (en) 2003-12-02
MXPA03004136A (es) 2003-08-19
EP1335906A1 (en) 2003-08-20
JP2004524279A (ja) 2004-08-12
AU2790502A (en) 2002-05-21
PE20020603A1 (es) 2002-07-20
KR20040004432A (ko) 2004-01-13
EP1335906B1 (en) 2006-09-27
ES2271100T3 (es) 2007-04-16
CA2427350A1 (en) 2002-05-16
PA8531701A1 (es) 2003-06-30
WO2002038551A1 (en) 2002-05-16
DE60123458D1 (de) 2006-11-09
DE60123458T2 (de) 2007-08-02
KR100611853B1 (ko) 2006-08-11
AR034700A1 (es) 2004-03-17
ATE340784T1 (de) 2006-10-15
DK1335906T3 (da) 2007-02-05
PT1335906E (pt) 2007-01-31
UY27018A1 (es) 2002-06-20
ZA200302970B (en) 2004-07-15
US20020086858A1 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
CN1274676C (zh) 喹啉和喹唑啉衍生物
CN1319950C (zh) 3－取代的－4－嘧啶酮衍生物
CN1473156A (zh) 嘧啶衍生物及其作为神经肽y受体配体的用途
CN1118459C (zh) 用作α1－肾上腺素能受体拮抗剂的嘧啶二酮、嘧啶三酮、三嗪二酮衍生物
CN1138546C (zh) 用作细胞因子的某些1,4,5-三取代咪唑化合物
CN1289087C (zh) 作为神经肽y拮抗剂的喹啉衍生物
CN1191239C (zh) 用于治疗病毒性疾病的吡唑衍生物
CN1556804A (zh) 3-取代的-4-嘧啶酮衍生物
CN1522249A (zh) 作为神经肽y受体的配体的喹啉衍生物
CN1741999A (zh) 用作GSK－3β抑制剂的哒嗪酮衍生物
CN1694708A (zh) TGFβ的抑制剂
CN1234031A (zh) 吲唑衍生物及其作为磷酸二酯酶(pde)iv型和肿瘤坏死因子(tnf)产生的抑制剂的应用
CN1150165C (zh) 用于治疗中枢神经系统紊乱的1-芳基磺酰基-2-芳基-吡咯烷衍生物
CN1653047A (zh) 抗炎症药物单环芳酰吡啶酮
CN1213306A (zh) 新的取代咪唑化合物
CN1527710A (zh) 作为促肾上腺皮质激素释放因子配体的取代的吡嗪酮、吡啶和嘧啶
CN1440393A (zh) 环状化合物
CN1305478A (zh) 用于治疗性功能障碍的吡唑并嘧啶酮cGMP PDE5抑制剂
CN1173132A (zh) 二氢嘧啶类化合物及其用途
CN1897936A (zh) 环状胍、含有这种化合物的组合物及其使用方法
CN1213307A (zh) 新的取代的咪唑化合物
CN1845921A (zh) 金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN1627945A (zh) 作为npy拮抗剂的喹啉衍生物
CN1440385A (zh) 用于治疗艾滋病的吡咯衍生物
CN1085550A (zh) 作为人类免疫缺乏病毒逆转录酶抑制剂的新的喹唑啉类

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication